Alzheimer's disease trials recruiting in Washington

All Alzheimer's disease trials nationally

Cities in Washington

Recruiting trials in Washington

• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
  NCT07094516 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · Washington: Seattle
• A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
  NCT06411561 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female) · Washington: Seattle
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Washington: Kirkland
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Washington: Seattle, Spokane
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · Washington: Bellevue, Tacoma
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
  NCT07589595 · Phase: Phase 2 · Ages: 55 Years to 85 Years · Sex: All (male and female) · Washington: Kirkland
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
  NCT06540833 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female) · Washington: Bellevue
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Washington: Bellevue
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Washington: Bellevue, Kirkland
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · Washington: Renton
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Washington: Seattle
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Washington: Seattle
• Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
  NCT06922188 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Dominantly Inherited Alzheimer Network (DIAN)
  NCT00869817 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Indian Transforming Alzheimer's Care Training (INTACT)
  NCT06397339 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Late Onset Alzheimer's Disease
  NCT05010603 · Phase: Not specified · Ages: 55 Years and older · Sex: All (male and female) · Washington: Seattle
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Washington: Kirkland
• Promoting Physical Activity in Older Hispanic/Latino(a) Adults
  NCT06362824 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 89 Years · Sex: All (male and female) · Washington: Seattle
• Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
  NCT06847321 · Phase: Phase 2 · Ages: 55 Years to 80 Years · Sex: All (male and female) · Washington: Bellevue